10 December 2021 | News
The funding will facilitate the IND filing of ZM008 and the start of Phase I trial in multiple cancers
Image credit: shutterstock.com
A Next generation Tumor-Directed IO therapeutics company Zumutor Biologics raises $6.2 million for its oncology molecule Zumutor is privileged to have a host of investors: Accel Partners, Bharat Innovation Fund (BIF) and the new incoming deep tech investor Siana Capital participate in a Series A4 Fundraise of $6.2 million.
“I am excited about ZM008, this funding will facilitate the IND filing of ZM008 and start of Phase I trial in multiple cancers,” Dr Maloy Ghosh, CSO, Zumutor said. “Zumutor’s poised well with elegant data for the next stage of value inflexion” Kavitha Iyer, CEO, Zumutor said.